{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:19:05Z","timestamp":1787624345000,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05483-7","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:05:20Z","timestamp":1779779120000},"page":"17665-17675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The synergistic efficacy of lupeol and enzalutamide potentiates anticancer activity, inducing apoptosis and cell cycle arrest in breast cancer cells"],"prefix":"10.1007","volume":"399","author":[{"given":"Nemat","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glowi","family":"Alasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Arockia","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Alaseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Sharique Ahmed","family":"Quadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogita","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"5483_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.500","volume":"5","author":"MA Babcook","year":"2014","unstructured":"Babcook MA, Sramkoski RM, Fujioka H, Daneshgari F, Almasan A, Shukla S, Nanavaty RR, Gupta S (2014) Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1-and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. Cell Death Dis 5:e1536","journal-title":"Cell Death Dis"},{"key":"5483_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1530\/ERC-16-0068","volume":"23","author":"F Caiazza","year":"2016","unstructured":"Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O\u2019Donovan N, Crown J, Duffy MJ (2016) Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells. Endocr Relat Cancer 23:323\u2013334","journal-title":"Endocr Relat Cancer"},{"key":"5483_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11912-014-0427-8","volume":"17","author":"K Chia","year":"2015","unstructured":"Chia K, O\u2019Brien M, Brown M, Lim E (2015) Targeting the androgen receptor in breast cancer. Curr Oncol Rep 17:4","journal-title":"Curr Oncol Rep"},{"key":"5483_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"702","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and quantification of their synergy using the Chou-Talalay method. Cancer Res 702:440\u2013446","journal-title":"Cancer Res"},{"key":"5483_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191805","volume":"13","author":"JA Del Campo","year":"2018","unstructured":"Del Campo JA, Garc\u00eda-Valdecasas M, Gil-G\u00f3mez A, Rojas \u00c1, Gallego P, Ampuero J, Gallego-Dur\u00e1n R, Pastor H, Grande L, Padillo FJ, Muntan\u00e9 J (2018) Simvastatin and metformin inhibit cell growth in Hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. PLoS ONE 13:e0191805","journal-title":"PLoS ONE"},{"key":"5483_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/1758834012458137","volume":"5","author":"J El-Amm","year":"2013","unstructured":"El-Amm J, Aragon-Ching JB (2013) The changing landscape in the treatment of metastatic castrationresistant prostate cancer. Ther Adv Med Oncol 5:25\u201340","journal-title":"Ther Adv Med Oncol"},{"key":"5483_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fendo.2018.00492","volume":"28","author":"P Giovannelli","year":"2018","unstructured":"Giovannelli P, Di Donato M, Galasso G, Di Zazzo E, Bilancio A, Migliaccio A (2018) The androgen receptor in breast cancer. Front Endocrinol 28:492","journal-title":"Front Endocrinol"},{"key":"5483_CR8","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212531","volume":"7","author":"C Guerrero-Garc\u00eda","year":"2018","unstructured":"Guerrero-Garc\u00eda C, Rubio-Guerra AF (2018) Combination therapy in the treatment of hypertension. Drugs Context 7:212531","journal-title":"Drugs Context"},{"key":"5483_CR9","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1128\/MCB.19.4.2690","volume":"19","author":"M Hinz","year":"1999","unstructured":"Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M (1999) NF-kappaB function in growth control: regulation of cyclin D1 expression and G0\/G1-to-S-phase transition. Mol Cell Biol 19:2690\u20132698","journal-title":"Mol Cell Biol"},{"key":"5483_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/1078-0432.CCR-12-2910","volume":"19","author":"J Hoffman-Censits","year":"2013","unstructured":"Hoffman-Censits J, Kelly WK (2013) Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res 19:1335\u20131339","journal-title":"Clin Cancer Res"},{"key":"5483_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12199-018-0724-1","volume":"23","author":"A Kapinova","year":"2018","unstructured":"Kapinova A, Kubatka P, Golubnitschaja O, Kello M, Zubor P, Solar P, Pec M (2018) Dietary phytochemicals in breast cancer research: anticancer effects and potential utility for effective chemoprevention. Environ Health Prev Med 23:1\u20138","journal-title":"Environ Health Prev Med"},{"key":"5483_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.34172\/apb.2024.035","volume":"14","author":"M Kaveh Zenjanab","year":"2024","unstructured":"Kaveh Zenjanab M, Hashemzadeh N, Alimohammadvand S, Sharifi-Azad M, Dalir Abdolahinia E, Jahanban-Esfahlan R (2024) Notch signaling suppression by golden phytochemicals: potential for cancer therapy. Adv Pharm Bull 14:302\u2013313","journal-title":"Adv Pharm Bull"},{"key":"5483_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116699","volume":"478","author":"MA Khan","year":"2023","unstructured":"Khan MA, Singh D, Jameel M, Maurya SK, Singh S, Akhtar K, Siddique HR (2023) Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy. Toxicol Appl Pharmacol 478:116699","journal-title":"Toxicol Appl Pharmacol"},{"key":"5483_CR14","first-page":"1","volume":"7","author":"PP Kushwaha","year":"2021","unstructured":"Kushwaha PP, Maurya SK, Singh A, Prajapati KS, Singh AK, Shuaib M, Kumar S (2021) Bulbine frutescens phytochemicals as novel ABC-transporter inhibitor: a molecular docking and molecular dynamics simulation study. J Cancer Metastasis Treat 7:1\u201313","journal-title":"J Cancer Metastasis Treat"},{"key":"5483_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115297","volume":"409","author":"PP Kushwaha","year":"2020","unstructured":"Kushwaha PP, Singh AK, Prajapati KS, Shuaib M, Fayez S, Bringmann G, Kumar S (2020) Induction of apoptosis in breast cancer cells by naphthylisoquinoline alkaloids. Toxicol Appl Pharmacol 409:115297","journal-title":"Toxicol Appl Pharmacol"},{"key":"5483_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116783","volume":"234","author":"PP Kushwaha","year":"2019","unstructured":"Kushwaha PP, Vardhan PS, Kapewangolo P, Shuaib M, Prajapati SK, Singh AK, Kumar S (2019) Bulbine frutescens phytochemical inhibits Notch signaling pathway and induces apoptosis in triple negative and luminal breast cancer cells. Life Sci 234:116783","journal-title":"Life Sci"},{"key":"5483_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s40203-022-00131-3","volume":"10","author":"SK Maurya","year":"2022","unstructured":"Maurya SK, Fatma H, Maurya AK, Mishra N, Siddique HR (2022) Role of lupeol in chemosensitizing therapy-resistant prostate cancer cells by targeting MYC, \u03b2-catenin and c-FLIP: in silico and in vitro studies. In Silico Pharmacol 10:16","journal-title":"In Silico Pharmacol"},{"key":"5483_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2174\/1381612826666200122122804","volume":"26","author":"SK Maurya","year":"2020","unstructured":"Maurya SK, Shadab GG, Siddique HR (2020) Chemosensitization of therapy resistant tumors: targeting multiple cell signaling pathways by Lupeol, a pentacyclic triterpene. Curr Pharm des 26:455\u2013465","journal-title":"Curr Pharm des"},{"key":"5483_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1756287214555336","volume":"7","author":"AS Merseburger","year":"2015","unstructured":"Merseburger AS, Haas GP, von Klot CA (2015) An update on enzalutamide in the treatment of prostate cancer. Ther Adv Urology 7:9\u201321","journal-title":"Ther Adv Urology"},{"key":"5483_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 65:55\u201363","journal-title":"J Immunol Methods"},{"key":"5483_CR21","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1128\/JCM.01161-13","volume":"51","author":"AM Payne","year":"2013","unstructured":"Payne AM, Zorman J, Horton M, Dubey S, ter Meulen J, Vora KA (2013) Caspase activation as a versatile assay platform for detection of cytotoxic bacterial toxins. J Clin Microbiol 51:2970\u20132976","journal-title":"J Clin Microbiol"},{"key":"5483_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nchembio814","volume":"2","author":"KS Putt","year":"2006","unstructured":"Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS, Kwon JT, Hwang SK, Jin H, Churchwell MI, Cho MH, Doerge DR, Helferich WG, Hergenrother PJ (2006) Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2:543\u2013550","journal-title":"Nat Chem Biol"},{"key":"5483_CR23","first-page":"757","volume":"17","author":"M Qiu","year":"2019","unstructured":"Qiu M, Zhang S, Ke L, Tang H, Zeng X, Liu J (2019) JS-K enhances chemosensitivity of prostate cancer cells to Taxol via reactive oxygen species activation. Oncol Lett 17:757\u2013764","journal-title":"Oncol Lett"},{"key":"5483_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3892\/etm.2011.212","volume":"2","author":"K Sakuma","year":"2011","unstructured":"Sakuma K, Kurosumi M, Oba H, Kobayashi Y, Takei H, Inoue K, Tabei T, Oyama T (2011) Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer. Exp Ther Med 2:257\u2013264","journal-title":"Exp Ther Med"},{"key":"5483_CR25","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-16-2339","volume":"23","author":"LS Schwartzberg","year":"2017","unstructured":"Schwartzberg LS, Yardley DA, Elias AD, Patel M, LoRusso P, Burris HA, Gucalp A, Peterson AC, Blaney ME, Steinberg JL, Gibbons JA (2017) A phase I\/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancer. Clin Cancer Res 23:4046\u20134054","journal-title":"Clin Cancer Res"},{"key":"5483_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1097-2765(02)00482-3","volume":"9","author":"Y Shi","year":"2002","unstructured":"Shi Y (2002) Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9:459\u2013470","journal-title":"Mol Cell"},{"issue":"13_Supplement","key":"5483_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1538-7445.AM2021-276","volume":"81","author":"HR Siddique","year":"2021","unstructured":"Siddique HR, Maurya SK (2021) Lupeol chemosensitize the cancer stem cells for Enzalutamide and ameliorate the Enzalutamide induced toxicity in prostate cancer. Cancer Res 81(13_Supplement):276","journal-title":"Cancer Res"},{"key":"5483_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.urolonc.2011.09.003","volume":"30","author":"EA Singer","year":"2012","unstructured":"Singer EA, Srinivasan R (2012) Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events. Urol Oncol 30:15\u201319","journal-title":"Urol Oncol"},{"key":"5483_CR29","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","volume":"36","author":"TA Traina","year":"2018","unstructured":"Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O\u2019Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R (2018) Enzalutamide for the treatment of androgen receptor\u2013expressing triple-negative breast cancer. J Clin Oncol 36:884\u2013890","journal-title":"J Clin Oncol"},{"key":"5483_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1756-9966-30-87","volume":"30","author":"RS Wong","year":"2011","unstructured":"Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30:87","journal-title":"J Exp Clin Cancer Res"},{"key":"5483_CR31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1101\/gad.12.6.806","volume":"12","author":"M Woo","year":"1998","unstructured":"Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D, Hakem A, McCurrach M, Khoo W, Kaufman SA (1998) Essential contribution of caspase 3\/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 12:806\u2013819","journal-title":"Genes Dev"},{"key":"5483_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW et al (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:1\u201313","journal-title":"Breast Cancer Res"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05483-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:24:26Z","timestamp":1787621066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05483-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5483"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05483-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}